Edwards Lifesciences Corp. a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately hundred countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna and Swan-Ganz. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and is registered in the United States Patent and Trademark Office.
Industry:MED PRODUCTS Sector: Medical Fiscal Year End:December Last Reported Quarter:03/31/12 Next EPS Date:07/19/12
Capital Structure Solvency and Cash Flow
Capital Structure
Cash and cash equivalents were $361.0 million at the end of September 30, 2010 versus $320 million at the end of June 30, 2010. Total debt was $101 million versus $178 million at the end of June 30, 2010. During the quarter, the company generated free cash flow of $80 million ($96 million cash from operations minus $16 million for capital expenditure) versus $32 million in the sequentially prior quarter. For FY10, the company still expects free cash flow of about $190–$200 million, excluding special items. Finally, the company continued with its share repurchase program during 3Q10, purchasing 4 million shares for about $200 million.
Last edited Mon Jan 03, 2011 02:37 AM by PushpanjaliBanerjee (Zacks Investment Research)
Governance Social Responsibility and Employee Relations
The analysts are concerned that the company’s current products will not be sufficient to meet its growth expectations. This implies that it must rely on uncertain new product introductions for growth.
Edwards LifeSciences faces competition from several large companies, including Medtronic and St. Jude Medical. The entry of new competing products or shifts in the pricing strategy of competitors, in all of Edwards’ markets, could have a material impact on future financial results.
Last edited Mon Jan 03, 2011 02:38 AM by PushpanjaliBanerjee (Zacks Investment Research)
Created by: WikiMigrationBot.
Last Modification: Thursday 03 of June, 2010 07:00:23 CDT by WikiMigrationBot.
